Aimmune Therapeutics to Participate in Three Investor Conferences in March
March 05 2019 - 8:00AM
Business Wire
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical
company developing treatments for life-threatening food allergies,
today announced that members of the Aimmune executive management
team will participate in three upcoming investor conferences in
March:
Event: Cowen and Company 39th Annual Healthcare
ConferenceDate: Tuesday, March 12, 2019Presentation
Time: 8:00 a.m. Eastern TimeLocation: Boston,
MAPresenter: Jayson Dallas, M.D., President and Chief
Executive Officer
Event: Barclays Global Healthcare ConferenceDate:
Wednesday, March 13, 2019Presentation Time: 2:05 p.m.
Eastern TimeLocation: Miami, FLPresenter: Eric
Bjerkholt, Chief Financial Officer, and Andrew Oxtoby, Chief
Commercial Officer
Event: 31st Annual ROTH ConferenceDate: Monday,
March 18, 2019Presentation Time: 1:30 p.m. Pacific Time/4:30
p.m. Eastern TimeLocation: Laguna Niguel,
CAPresenter: Eric Bjerkholt, Chief Financial Officer
Live webcasts of the presentations will be accessible on the
Events page under the Investor Relations section of the Aimmune
website at www.aimmune.com. Replays of the webcasts will be
available following each webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a biopharmaceutical company
developing oral treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™)
approach is intended to provide meaningful levels of protection
against allergic reactions resulting from accidental exposure to
food allergens by desensitizing patients with defined, precise
amounts of key allergens. Aimmune’s first investigational biologic
product using CODIT™, AR101 for the treatment of peanut allergy,
has received the FDA’s Breakthrough Therapy Designation for the
desensitization of peanut-allergic patients 4-17 years of age.
Aimmune’s regulatory filing for marketing approval of AR101 in the
United States (submitted 4Q18) is based on data from the pivotal
Phase 3 PALISADE clinical trial of AR101, which in 4-17 year-old
subjects met its primary and key secondary endpoints, and
additional ongoing and completed AR101 clinical trials. Aimmune
expects to file for marketing approval of AR101 in Europe mid-2019.
Aimmune has filed an IND application for its second product, AR201,
for the treatment of egg allergy and intends to start a randomized
Phase 2 clinical trial mid-2019. For more information, please see
www.aimmune.com.
This press release concerns AR101, a product candidate that is
under clinical investigation, and AR201, a product candidate that
Aimmune expects will be under clinical investigation in 2019.
Neither AR101 nor AR201 has been approved for marketing by the FDA
or the European Medicines Agency (EMA). AR101 and AR201 are
currently limited to investigational use, and no representation is
made as to their safety or effectiveness for the purposes for which
they are being investigated.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190305005339/en/
InvestorsLaura Hansen, Ph.D.,
650-396-3814lhansen@aimmune.comMediaAlison Marquiss,
650-376-5583amarquiss@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Sep 2023 to Sep 2024